Copyright ©2008 The WJG Press and Baishideng.
World J Gastroenterol. Sep 21, 2008; 14(35): 5377-5384
Published online Sep 21, 2008. doi: 10.3748/wjg.14.5377
Table 5 Results of studies of molecularly targeted agents in patients with neuroendocrine tumours[54,55]
AgentResponse rate (%)PFS rate (%)/Duration
VEGF monoclonal antibody
Bevacizumab[56]1895 at 18 wk
mTOR inhibitor
RAD001 (everolimus)1371 at 24 wk
Temsirolimus[57]5.650 at 6 mo
Sunitinib10Median, 42 wk
VatalanibIn progress(time to progression)
SorafenibIn progress
PazopanibIn progress
PDGFR/Kit/Abl inhibitor
Imatinib[58]4Median, 5.9 mo
EGFR inhibitor
Gefitinib461 (carcinoids) and 31 (pancreatic tumor) at 6 mo
Bortezomib[59]0Median, 3 mo
(Time to treatment failure)